HCID 59291169, compound → HCID 68592975, compound

Temperature

90 °C

A mixture of 3-(2-chloro-5-methylpyrimidin-4-yl)pyrazolo[1,5-a]pyridine (400 mg, 1.55 mmol), 1-(6-amino-5-methoxyindolin-1-yl)ethanone (341 mg, 1.55 mmol) and diacetoxypalladium (34.9 mg, 0.16 mmol) 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (97 mg, 0.16 mmol) cesium carbonate (759 mg, 2.33 mmol) were degassed with nitrogen then dioxane (7 mL) was added to mixture and the solution was degassed under vacuum and placed under nitrogen. The resulting suspension was stirred at 90 °C for 5hours. Control uplc/ms OK Control t.l.c : 100%EtOAc and 5%MeOH/CH2Cl2 After cooling, the mixture was filtered and the filtrate evaporated to dryness after addition of silica gel The crude product was purified by flash chromatography on silica gel 45g Merck column solid injectioneluting with 0 to 10%MeOH/EtOAc. The solvent was evaporated to dryness to afford 1-(5-methoxy-6-(5-methyl-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)indolin-1-yl)ethanone (301 mg, 46.8 %) as a orange solid.

ORD record

ord-019ad9f92b5c40ecbf5416e8a6461063

Source dataset

750 AstraZeneca ELN dataset

Original link

View source